Chen Zi-Rong, Chen Shin-Chieh, Wan Tsung-Yao, Chuang Lan-Hsin, Chen Hung-Chi, Yeh Lung-Kun, Kuo Yu-Kai, Wu Pei-Chang, Chen Yun-Wen, Lai Ing-Chou, Hwang Yih-Shiou, Liu Chun-Fu
College of Medicine, Chang Gung University, Taoyuan 333, Taiwan.
Department of Environmental and Occupational Medicine, National Taiwan University Hospital, Taipei 100, Taiwan.
J Clin Med. 2023 Aug 10;12(16):5220. doi: 10.3390/jcm12165220.
(1) Purpose: To investigate the efficacy of myopia treatment in children using atropine 0.125% once every two nights (QON) compared with atropine 0.125% once every night (HS). (2) Methods: This retrospective cohort study reviewed the medical records of two groups of children with myopia. Group 1 comprised children treated with atropine 0.125% QON, while group 2 included children treated with atropine 0.125% HS. The first 6 months of data of outcome measurements were subtracted as washout periods in those children undergoing both atropine QON and HS treatment. The independent t-test and Pearson's chi-square test were used to compare the baseline clinical characteristics between the two groups. A generalized estimating equations (GEE) model was used to determine the factors that influence treatment effects. (3) Results: The average baseline ages of group 1 (38 eyes from 19 patients) and group 2 (130 eyes from 65 patients) were 10.6 and 10.2 years, respectively. There were no significant differences in axial length (AL) or cycloplegic spherical equivalent (SEq) at baseline or changes of them after 16.9 months of follow-up. GEE showed that the frequency of atropine 0.125% use has no association with annual AL (QON vs. HS: 0.16 ± 0.10 vs. 0.18 ± 0.12) and SEq (QON vs. HS: -0.29 ± 0.44 vs. -0.34 ± 0.36) changes in all children with myopia. It also showed that older baseline age (B = -0.020, < 0.001) was associated with lesser AL elongation. (4) Conclusion: The treatment effects of atropine 0.125% HS and QON were similar in this pilot study. The use of atropine 0.125% QON may be an alternative strategy for children who cannot tolerate the side effects of atropine 0.125% HS. This observation should be confirmed with further large-scale studies.
(1) 目的：研究每晚一次使用0.125%阿托品（HS）与每两晚一次使用0.125%阿托品（QON）治疗儿童近视的疗效。(2) 方法：这项回顾性队列研究回顾了两组近视儿童的病历。第1组包括接受0.125%阿托品QON治疗的儿童，而第2组包括接受0.125%阿托品HS治疗的儿童。在那些同时接受阿托品QON和HS治疗的儿童中，将结局测量的前6个月数据作为洗脱期减去。使用独立t检验和Pearson卡方检验比较两组之间的基线临床特征。使用广义估计方程（GEE）模型来确定影响治疗效果的因素。(3) 结果：第1组（19例患者的38只眼）和第2组（65例患者的130只眼）的平均基线年龄分别为10.6岁和10.2岁。在基线时的眼轴长度（AL）或睫状肌麻痹等效球镜度数（SEq）以及随访16.9个月后的变化方面，两组之间均无显著差异。GEE显示，在所有近视儿童中，0.125%阿托品的使用频率与年度AL变化（QON与HS：0.16±0.10与0.18±0.12）和SEq变化（QON与HS：-0.29±0.44与-0.34±0.36）无关。它还显示，基线年龄较大（B = -0.020，<0.001）与较小的AL伸长有关。(4) 结论：在这项初步研究中，0.125%阿托品HS和QON的治疗效果相似。对于无法耐受0.125%阿托品HS副作用的儿童，使用0.125%阿托品QON可能是一种替代策略。这一观察结果应通过进一步的大规模研究加以证实。
